Payment overview · 2025
General Payments
$703.26
31 reported records · 13 companies
Healthcare provider profile · identity verified
Michael A Campbell, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · FALL RIVER, MA · NPI 1376523621
Verified facts
What the public records show
CMS Open Payments records show Michael A Campbell, D.O. received $703.26 in general payments during 2025 across 31 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1017 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $209.82 | 29.8% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $135.42 | 19.3% | 8 | 2025 |
| QOL Medical, LLC | Unresolved — no canonical attribution shown | $52.89 | 7.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $51.94 | 7.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.57 | 7.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.57 | 6.9% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $31.97 | 4.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.34 | 3.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.04 | 3.4% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $23.03 | 3.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.91 | 2.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.17 | 2.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.59 | 2.1% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $703.26 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $189.90 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $129.79 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $109.87 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $99.86 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.05 | 4 | 2025 |
Source payment records
|
|||||
| Sucraid Normalized: sucraid |
Drug | QOL Medical, LLC | $52.89 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $51.94 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $50.57 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $48.57 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $48.57 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.56 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $31.97 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $31.97 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $28.54 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.34 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.04 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.04 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $23.03 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $23.03 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.59 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1017 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 229 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 34 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
143 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
229 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
180 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1017 | 49 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trazodone Hcl | Trazodone Hcl | 1678 | 82 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1543 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1206 | 88 |
| Famotidine | Famotidine | 1097 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 1075 | 123 |
| Gabapentin | Gabapentin | 1045 | 61 |
| Eliquis | Apixaban | 1017 | 49 |
| Mirtazapine | Mirtazapine | 949 | 43 |
| Lisinopril | Lisinopril | 857 | 106 |
| Furosemide | Furosemide | 776 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 745 | 34 |
| Omeprazole | Omeprazole | 631 | 86 |
| Metoprolol Tartrate | Metoprolol Tartrate | 627 | 39 |
| Sertraline Hcl | Sertraline Hcl | 594 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 531 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 531 | 39 |
| Topiramate | Topiramate | 497 | 19 |
| Metformin Hcl Er | Metformin Hcl | 436 | 48 |
| Allopurinol | Allopurinol | 418 | 56 |
| Buspirone Hcl | Buspirone Hcl | 352 | 25 |
| Metformin Hcl | Metformin Hcl | 347 | 35 |
| Risperidone | Risperidone | 300 | 11 |
| Finasteride | Finasteride | 286 | 20 |
| Simvastatin | Simvastatin | 262 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 255 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 248 | 39 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 231 | 13 |
| Divalproex Sodium | Divalproex Sodium | 230 | 14 |
| Farxiga | Dapagliflozin Propanediol | 229 | 24 |
| Olanzapine | Olanzapine | 227 | suppressed |
| Potassium Chloride | Potassium Chloride | 226 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 216 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 212 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 211 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 208 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 204 | 12 |
| Losartan Potassium | Losartan Potassium | 198 | 30 |
| Montelukast Sodium | Montelukast Sodium | 189 | 27 |
| Valsartan | Valsartan | 187 | 32 |
| Colestipol Hcl | Colestipol Hcl | 185 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 182 | 21 |
| Jardiance | Empagliflozin | 180 | 26 |
| Levetiracetam | Levetiracetam | 177 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 176 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 176 | 26 |
| Xarelto | Rivaroxaban | 176 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 174 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 159 | 32 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 155 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 153 | suppressed |
| Lorazepam | Lorazepam | 148 | 30 |
| Alprazolam | Alprazolam | 144 | 35 |
| Linzess | Linaclotide | 143 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 18 |
| Prednisone | Prednisone | 139 | 43 |
| Lamotrigine | Lamotrigine | 129 | 13 |
| Donepezil Hcl | Donepezil Hcl | 119 | suppressed |
| Baclofen | Baclofen | 116 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 57 |
| Carvedilol | Carvedilol | 111 | 15 |
| Gemfibrozil | Gemfibrozil | 108 | suppressed |
| Memantine Hcl | Memantine Hcl | 107 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 106 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 105 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 105 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 20 |
| Carbamazepine | Carbamazepine | 103 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 103 | suppressed |
| Atenolol | Atenolol | 101 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 100 | 18 |
| Ezetimibe | Ezetimibe | 99 | 22 |
| Primidone | Primidone | 99 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 97 | suppressed |
| Spironolactone | Spironolactone | 96 | 11 |
| Repaglinide | Repaglinide | 94 | suppressed |
| Aripiprazole | Aripiprazole | 93 | suppressed |
| Glipizide | Glipizide | 92 | suppressed |
| Ozempic | Semaglutide | 92 | 22 |
| Torsemide | Torsemide | 92 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 24 |
| Bupropion Hcl Sr | Bupropion Hcl | 88 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 87 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 84 | 24 |
| Meloxicam | Meloxicam | 83 | 18 |
| Nortriptyline Hcl | Nortriptyline Hcl | 83 | 11 |
| Anastrozole | Anastrozole | 81 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 81 | suppressed |
| Ibuprofen | Ibuprofen | 80 | 27 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 80 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 34 |
| Bumetanide | Bumetanide | 77 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 16 |
| Sucralfate | Sucralfate | 71 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 70 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 67 | 18 |
| Labetalol Hcl | Labetalol Hcl | 66 | suppressed |
| Acarbose | Acarbose | 65 | suppressed |
| Calcitriol | Calcitriol | 64 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 64 | suppressed |
| Cephalexin | Cephalexin | 61 | suppressed |
| Pregabalin | Pregabalin | 61 | 12 |
| Tradjenta | Linagliptin | 61 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 60 | 24 |
| Bethanechol Chloride | Bethanechol Chloride | 59 | suppressed |
| Rexulti | Brexpiprazole | 59 | suppressed |
| Sotalol | Sotalol Hcl | 59 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 58 | 13 |
| Propranolol Hcl | Propranolol Hcl | 56 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 56 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 11 |
| Amoxicillin | Amoxicillin | 54 | 36 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 53 | 15 |
| Acetazolamide Er | Acetazolamide | 52 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 33 |
| Entresto | Sacubitril/Valsartan | 52 | suppressed |
| Metolazone | Metolazone | 52 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 51 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 51 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 50 | 26 |
| Myrbetriq | Mirabegron | 49 | suppressed |
| Azithromycin | Azithromycin | 48 | 41 |
| Cinacalcet Hcl | Cinacalcet Hcl | 48 | suppressed |
| Colchicine | Colchicine | 48 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Mesalamine Er | Mesalamine | 46 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 30 |
| Naproxen | Naproxen | 45 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 11 |
| Celecoxib | Celecoxib | 43 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 41 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 41 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 40 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 39 | suppressed |
| Nystatin | Nystatin | 39 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 39 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Rybelsus | Semaglutide | 34 | 11 |
| Calcium Acetate | Calcium Acetate | 33 | suppressed |
| Levemir | Insulin Detemir | 33 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 32 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Budesonide | Budesonide | 29 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 14 |
| Dapagliflozin | Dapagliflozin Propanediol | 26 | suppressed |
| Fentanyl | Fentanyl | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 18 |
| Silver Sulfadiazine | Silver Sulfadiazine | 26 | 11 |
| Nystop | Nystatin | 25 | 12 |
| Albuterol Sulfate | Albuterol Sulfate | 24 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Clotrimazole | Clotrimazole | 24 | 16 |
| Lidocaine | Lidocaine | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Oxycontin | Oxycodone Hcl | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Erythromycin | Erythromycin Base | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Insulin Aspart | Insulin Aspart | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Probenecid | Probenecid | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $703.26 · 31 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APTIMA, BREZTRI, CAPVAXIVE, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, Sucraid, THINPREP 2000 PROCESSOR, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Wegovy, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error